CLINICAL TRIALS PROFILE FOR ENTRESTO
✉ Email this page to a colleague
All Clinical Trials for entresto
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02636283 ↗ | Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease | Terminated | American Heart Association | Phase 2 | 2017-12-31 | This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs. |
| NCT02636283 ↗ | Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease | Terminated | University of Minnesota | Phase 2 | 2017-12-31 | This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs. |
| NCT02636283 ↗ | Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease | Terminated | University of Minnesota - Clinical and Translational Science Institute | Phase 2 | 2017-12-31 | This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs. |
| NCT02682719 ↗ | Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation | Active, not recruiting | Novartis Ireland Ltd | Phase 2 | 2015-12-16 | Sacubitril-valsartan, an Angiotensin Receptor Blocker-Neprilysin Inhibitor (ARNI), currently marketed for the management of heart failure, has been shown to reduce cardiovascular morbidity and mortality in stage C heart failure with reduced ejection fraction. In stage C HFpEF, sacubitril-valsartan has also been shown to reduce left atrial volume index measured using echocardiography over a 9 month timeframe. The PARABLE study investigates the hypothesis that sacubitril-valsartan can provide benefits in terms of left atrial structure and function as well as left ventricular structure and function in asymptomatic (stage A/B HFpEF) patients. This is a prospective, randomised, double-blind, double-dummy, phase II study design. The patient population will have hypertension and/or diabetes together with preserved ejection fraction, elevated natriuretic peptide (NP) and abnormal left atrial volume index (LAVI, > 28 mL/m2). |
| NCT02682719 ↗ | Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation | Active, not recruiting | The Heartbeat Trust | Phase 2 | 2015-12-16 | Sacubitril-valsartan, an Angiotensin Receptor Blocker-Neprilysin Inhibitor (ARNI), currently marketed for the management of heart failure, has been shown to reduce cardiovascular morbidity and mortality in stage C heart failure with reduced ejection fraction. In stage C HFpEF, sacubitril-valsartan has also been shown to reduce left atrial volume index measured using echocardiography over a 9 month timeframe. The PARABLE study investigates the hypothesis that sacubitril-valsartan can provide benefits in terms of left atrial structure and function as well as left ventricular structure and function in asymptomatic (stage A/B HFpEF) patients. This is a prospective, randomised, double-blind, double-dummy, phase II study design. The patient population will have hypertension and/or diabetes together with preserved ejection fraction, elevated natriuretic peptide (NP) and abnormal left atrial volume index (LAVI, > 28 mL/m2). |
| NCT02682719 ↗ | Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation | Active, not recruiting | Mark Ledwidge | Phase 2 | 2015-12-16 | Sacubitril-valsartan, an Angiotensin Receptor Blocker-Neprilysin Inhibitor (ARNI), currently marketed for the management of heart failure, has been shown to reduce cardiovascular morbidity and mortality in stage C heart failure with reduced ejection fraction. In stage C HFpEF, sacubitril-valsartan has also been shown to reduce left atrial volume index measured using echocardiography over a 9 month timeframe. The PARABLE study investigates the hypothesis that sacubitril-valsartan can provide benefits in terms of left atrial structure and function as well as left ventricular structure and function in asymptomatic (stage A/B HFpEF) patients. This is a prospective, randomised, double-blind, double-dummy, phase II study design. The patient population will have hypertension and/or diabetes together with preserved ejection fraction, elevated natriuretic peptide (NP) and abnormal left atrial volume index (LAVI, > 28 mL/m2). |
| NCT02754518 ↗ | Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis | Completed | University of Chicago | Phase 4 | 2016-04-01 | This study intends to measure the effects of valsartan/sacubitril compared to baseline standard medical heart failure therapy on reverse remodeling using echocardiographic endocardial surface analysis techniques to assess changes in ventricular volume, function, and shape. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for entresto
Condition Name
Clinical Trial Locations for entresto
Trials by Country
Clinical Trial Progress for entresto
Clinical Trial Phase
Clinical Trial Sponsors for entresto
Sponsor Name
